Prothena Corporation PLC (NASDAQ:PRTA) – Stock analysts at Oppenheimer Holdings upped their Q3 2017 earnings per share (EPS) estimates for shares of Prothena Corporation PLC in a research report issued to clients and investors on Wednesday. Oppenheimer Holdings analyst J. Olson now forecasts that the biotechnology company will post earnings per share of ($1.44) for the quarter, up from their prior estimate of ($1.62). Oppenheimer Holdings has a “Outperform” rating and a $70.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Prothena Corporation PLC’s Q4 2017 earnings at ($1.64) EPS, FY2017 earnings at ($4.54) EPS, FY2018 earnings at ($4.79) EPS, FY2019 earnings at ($4.98) EPS, FY2020 earnings at ($1.81) EPS and FY2021 earnings at ($1.79) EPS.

Other equities analysts have also recently issued reports about the company. Zacks Investment Research upgraded Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $59.00 target price for the company in a research note on Tuesday, April 18th. BidaskClub cut Prothena Corporation PLC from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Jefferies Group LLC started coverage on Prothena Corporation PLC in a research note on Monday, July 10th. They set a “buy” rating and a $100.00 target price for the company. BTIG Research started coverage on Prothena Corporation PLC in a research note on Friday, May 19th. They set a “buy” rating and a $80.00 target price for the company. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Prothena Corporation PLC in a research note on Tuesday, May 16th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $76.45.

ILLEGAL ACTIVITY WARNING: “Q3 2017 EPS Estimates for Prothena Corporation PLC Lifted by Analyst (PRTA)” was first posted by Daily Political and is the property of of Daily Political. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/08/11/q3-2017-eps-estimates-for-prothena-corporation-plc-lifted-by-analyst-prta.html.

Shares of Prothena Corporation PLC (NASDAQ PRTA) opened at 55.64 on Friday. Prothena Corporation PLC has a 12-month low of $40.58 and a 12-month high of $69.53. The firm’s 50-day moving average is $60.52 and its 200-day moving average is $54.85. The firm’s market cap is $2.12 billion.

Prothena Corporation PLC (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.43. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 34.50%. The company had revenue of $26.81 million for the quarter, compared to analysts’ expectations of $16.08 million. During the same quarter last year, the company earned ($1.18) earnings per share. The firm’s revenue for the quarter was up 7951.1% on a year-over-year basis.

In related news, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction on Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the transaction, the director now directly owns 6,345 shares in the company, valued at $368,707.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the firm’s stock in a transaction on Monday, July 17th. The stock was sold at an average price of $64.89, for a total value of $324,450.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at $324,450. The disclosure for this sale can be found here. Company insiders own 3.10% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Woodford Investment Management Ltd boosted its position in shares of Prothena Corporation PLC by 7.7% in the first quarter. Woodford Investment Management Ltd now owns 11,106,211 shares of the biotechnology company’s stock valued at $619,282,000 after buying an additional 795,700 shares during the period. FMR LLC boosted its position in shares of Prothena Corporation PLC by 9.4% in the first quarter. FMR LLC now owns 5,659,308 shares of the biotechnology company’s stock valued at $315,733,000 after buying an additional 486,044 shares during the period. Wellington Management Group LLP boosted its position in shares of Prothena Corporation PLC by 4.6% in the first quarter. Wellington Management Group LLP now owns 3,158,012 shares of the biotechnology company’s stock valued at $176,185,000 after buying an additional 138,979 shares during the period. BlackRock Inc. boosted its position in shares of Prothena Corporation PLC by 7.8% in the second quarter. BlackRock Inc. now owns 2,947,512 shares of the biotechnology company’s stock valued at $159,519,000 after buying an additional 213,578 shares during the period. Finally, Palo Alto Investors LLC boosted its position in shares of Prothena Corporation PLC by 6.2% in the first quarter. Palo Alto Investors LLC now owns 1,055,855 shares of the biotechnology company’s stock valued at $58,906,000 after buying an additional 62,000 shares during the period.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Earnings History and Estimates for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.